-
Children's Chiqiao Qingre Syrup Approved for Marketing
2023-11-17
Recently, the Category 2.2 moidfied new traditional Chinese medicine Children's Chiqiao Qingre Syrup of Jumpcan Pharmaceutical Group Co., Ltd. is approved for marketing by China NMPA. It is a pediatric drug with highly increased compliance after the modification of dosage form.
-
Vebreltinib Enteric Capsules Approved with Conditions for Marketing
2023-11-16
Recently, the Category 1 innovative drug Vebreltinib Enteric Capsules of Beijing Pearl Biotechnology Limited Liability Company was approved for marketing with conditions by China NMPA.
-
Xianglei Tangzu Cream Approved with Conditions for Marketing
2023-11-14
Recently, the natural products Category 1.1 innovative drug Xianglei Tangzu Cream (Fespixon Cream) of Oneness Biotech Co., Ltd. was approved for marketing with conditions by China NMPA.
-
Glofitamab Injection Approved with Conditions for Marketing
2023-11-08
Recently, the Glofitamab Injection (trade name: 高罗华/Columvi) of Roche Pharma (Schweiz) AG is approved with conditions by China NMPA.
-
Aponermin for Injection Approved for Marketing by China NMPA
2023-11-02
Recently, the Aponermin for Injection (Chinese trade name:沙艾特) of Wuhan HITECK biopharmaceutical Co., Ltd. is approved by China NMPA.
-
Children's Zibei Xuanfei Syrup Approved for Marketing
2023-10-19
Recently, the Category 1.1 innovative traditional Chinese medicine Children's Zibei Xuanfei Syrup of Jianmin Pharmaceutical Group Co., Ltd. is approved for marketing by China NMPA.
